Adipose-derived stem cells from pregnant women show higher proliferation rate unrelated to estrogen.
Ng LW., Yip SK., Wong HK., Yam GH., Liu YM., Lui WT.
Laboratory Study with a reported sample of 15, published in Hum Reprod (2009) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Hum Reprod (2009)
- Country
- England
- Reported sample size
- 15
- Source database
- PubMed
- PMID
- 19181742
- DOI
- 10.1093/humrep/dep001
- Citations
- 18
Abstract (original English)
Adipose tissue contains an abundant population of multipotent adipose-derived stem cells (ASCs) and has been an excellent source of mesenchymal stem cells for cell therapy and tissue engineering. To ensure successful cell therapies, consistency of stem cell performance across donors is critical. However, the effect of the donor's reproductive status on ASC proliferation rate and differentiation capacity is undefined. We investigated whether the yield and function of ASCs are affected by the woman's reproductive status: pregnancy, premenopause or menopause. ASCs were isolated from the abdomen of 15 women and their proliferation rates and differentiation capacities were compared by cell count. The capacity of ASCs to differentiate into the chondrogenic lineage was investigated by quantitative real-time polymerase chain reaction and immunohistochemistry. There was no significant difference in the differentiation capacity between the three groups, whereas the proliferation rate of ASCs from pregnant women was significantly higher than from the other two groups (P < 0.05). The proliferation rate of ASCs after estrogen treatment remained unchanged. Despite the higher proliferation rate in pregnant women, ASCs showed consistency in cell differentiation capacity and were unaffected by donor status. This suggests that factors other than estrogen are responsible for the difference in pro
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.